Medical Condition News

RSS

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Scientists develop first cell-based model of Alzheimer's disease

A team of scientists at The New York Stem Cell Foundation (NYSCF) Laboratory led by Scott Noggle, PhD, NYSCF-Charles Evans Senior Research Fellow for Alzheimer's Disease, has developed the first cell-based model of Alzheimer's disease (AD) by reprogramming skin cells of Alzheimer's patients to become brain cells that are affected in Alzheimer's.

17 Jul 2012

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.

17 Jul 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

Genetic tests for Alzheimer’s disease a comfort for the majority

Several genetic tests are available for Alzheimer’s disease, both for the general public and for those with a family history of the disease. As direct-to-consumer testing over the internet rises, so have concerns over how people will handle information related to their risk of developing Alzheimer’s disease.

17 Jul 2012

People with amnestic MCI more likely to die

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that people with a form of mild cognitive impairment (MCI), a risk factor for developing Alzheimer's disease, have twice the risk of dying compared with cognitively normal people. Those with dementia have three times the risk.

17 Jul 2012

Patients with early-stage MS show sodium accumulation in specific brain regions

A buildup of sodium in the brain detected by magnetic resonance imaging (MRI) may be a biomarker for the degeneration of nerve cells that occurs in patients with multiple sclerosis (MS), according to a new study published online in the journal Radiology.

17 Jul 2012

Studies provide evidence of connections between MCI and negative health outcomes

Two studies presented today at the Alzheimer's Association International Conference 2012 (AAIC 2012) in Vancouver provide evidence of connections between mild cognitive impairment (MCI) and negative health outcomes – increased isolation and death.

17 Jul 2012

New CD141hi DC subset plays a critical role in activating immune response against pathogens

Scientists at A*STAR's Singapore Immunology Network (SIgN), in collaboration with Newcastle University, UK, the Singapore Institute of Clinical Sciences and clinicians from multiple hospitals in Singapore, have identified a new subset of dendritic cells (DCs) in human peripheral tissue which have a critical role in activating our immune response against harmful pathogens.

17 Jul 2012

Obesity leads to more doctor visits than smoking

Statistics show that today, almost one in four Canadians is obese. A deadly trend that has been on the rise for the last thirty years, obesity is associated with diabetes, heart disease and cancer. But is the obesity epidemic putting more pressure on an already strained Canadian health care system?

17 Jul 2012

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

A new multicenter study published in The Open Pain Journal showed that daily consumption of the pentose carbohydrate D-ribose resulted in an average energy boost of 61 percent among patients diagnosed with Chronic Fatigue Syndrome (CFS) and fibromyalgia (FMS).

17 Jul 2012

Stress management treatment reduces formation of new brain lesions in people with MS

Research conducted by Jesus Lovera, MD, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has shown that stress management treatment significantly reduced the formation of new brain lesions in people with multiple sclerosis (MS) over the course of treatment.

17 Jul 2012

New automated method for identification of lung nodules in community-based settings

Pulmonary nodules are common, but few studies of lung nodule identification and clinical evaluation have been performed in community settings. Researchers from Kaiser Permanente Southern California identified 7,112 patients who had one or more nodules by using existing information within the electronic medical record.

17 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent mutations observed in acute myeloid leukemias. FLT3 mutants are thought to activate several signaling pathways that contribute to cancer development.

17 Jul 2012

Osteoporosis and sarcopenia: researchers at UMKC receive $8.3 million to study relationship

The University of Missouri-Kansas City has received a five-year, $8.3 million grant from the National Institute on Aging, part of the National Institutes of Health, to study the relationship between osteoporosis (loss of bone density) and sarcopenia (loss of muscle mass) as people age.

16 Jul 2012

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase I trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis.

16 Jul 2012

Medical Condition News

Ampio announces advancement of NCE001 to preclinical development

Scientists develop first cell-based model of Alzheimer's disease

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

Genetic tests for Alzheimer’s disease a comfort for the majority

People with amnestic MCI more likely to die

Patients with early-stage MS show sodium accumulation in specific brain regions

Studies provide evidence of connections between MCI and negative health outcomes

New CD141hi DC subset plays a critical role in activating immune response against pathogens

Obesity leads to more doctor visits than smoking

D-ribose effective in improving QOL in energy-depleted patients with FMS/CFS

Stress management treatment reduces formation of new brain lesions in people with MS

New automated method for identification of lung nodules in community-based settings

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

Targeting CDK1 pathway may be efficacious for acute myeloid leukemias with FLT3 mutation

Osteoporosis and sarcopenia: researchers at UMKC receive $8.3 million to study relationship

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

FDA clears TMI’s Glider PTCA balloon catheter

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

St. Joseph Hospital initiates enrollment in Medtronic’s SYMPLICITY HTN-3 trial for hypertension

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Latest News